Novo Nordisk’s Pill Price War Intensifies as AI Strategy Unfolds
Novo Nordisk slashes prices and partners with OpenAI as its oral weight-loss drug faces fierce competition from Eli…
Novo Nordisk’s Triple-Thrust Strategy to Revive a Slumping Stock
Novo Nordisk launches Wegovy HD injection and oral pill to combat Eli Lilly, gains EU storage advantage, and…
Novo Nordisk’s Pill and Needle Strategy Faces a Competitive and Financial Crossroads
Novo Nordisk launches high-dose & oral Wegovy in the US and eases EU cold-chain rules to compete with…
New Drugs and a Massive Buyback Amid Market Pressure
Novo Nordisk’s share price hits 12-month low despite a major buyback and launch of Wegovy HD & oral…
Orsted’s US Offshore Wind Strategy Gains Investor Confidence
Orsteds, Offshore
22.03.2026 – 04:57:43 | boerse-global.de
Orsted’s resilient US offshore wind operations boost…
Novo Nordisk’s Subscription Strategy to Counter Market Pressures
Novo Nordisk counters revenue decline and Eli Lilly’s market lead with a Wegovy subscription model, aiming to lock…
European Lithium Shifts Strategy to Greenland Rare Earths Venture
European Lithium pivots from Austrian lithium to Greenland rare earths, launching a share buyback after a 40% concentration…
European Lithium Shifts Strategy to Greenland Rare Earths Venture
European Lithium pivots from Austrian lithium to Greenland rare earths, launching a share buyback after a 40% concentration…
Geopolitical Shifts Fuel Optimism for Ørsted’s Offshore Wind Strategy
Geopolitical, Shifts
04.04.2026 – 05:46:45 | boerse-global.de
Ørsted shares surge on Bank of America…
Geopolitical Shifts Fuel Optimism for Ørsted’s Offshore Wind Strategy
Geopolitical, Shifts
04.04.2026 – 05:46:45 | boerse-global.de
Ørsted shares surge on Bank of America…
Novo Nordisk Launches Aggressive Pricing Strategy for Wegovy Amid Restructuring
Novo Nordisk introduces a $249/month Wegovy subscription to boost patient loyalty and undercut Eli Lilly, while cutting 400…
Novo Nordisk Shareholders Approve Capital Strategy and Board Refresh
Novo Nordisk shareholders approved a 10% share buyback, a DKK 44.65M capital increase, and a DKK 11.70 dividend…